Genovefa Papanicolaou, MD
Infectious Disease · New York, NYNPI 1497726301
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (34.7%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Merck at 59.6% of the total. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $1316.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$125K
- Takeda Pharmaceuticals U.S.A., Inc.$19K
- CSL Behring$15K
- Biotest AG$9K
- Partner Therapeutics, Inc.$9K
- Shionogi Inc$8K
- plus $24K from 10 others
Across 326 payments — averaging $7782.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.1M
- Takeda Pharmaceuticals U.S.A., Inc.$234K
- Astellas Pharma Global Development$108K
- Shire North American Group Inc$101K
- Gilead$21K
- Octapharma USA, Inc.$9K
What the payments were for
- Consulting fees$71,90334%
- Speaking & faculty fees$63,03230%
- Travel & lodging$72,58235%
- Food & beverage$1,8201%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 84 | $124,825 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $19,256 |
| CSL Behring | 7 | $14,905 |
| Biotest AG | 2 | $9,211 |
| Partner Therapeutics, Inc. | 4 | $9,173 |
| Shionogi Inc | 14 | $7,983 |
| ADMA Biomanufacturing LLC | 1 | $5,144 |
| Janssen Research & Development, LLC | 10 | $4,750 |
| Octapharma USA, Inc. | 6 | $3,896 |
| Siemens Medical Solutions USA, Inc. | 2 | $3,735 |
| Astellas Pharma US Inc | 10 | $2,455 |
| Regeneron | 3 | $2,345 |
| Gilead | 2 | $1,379 |
| Astellas Pharma Global Development | 4 | $210 |
| Melinta Therapeutics, LLC | 1 | $73 |
| AstraZeneca | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$209,357 in reported general payments places this provider in the 95th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Judith AbergNew York$104K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
- Joseph FeczkoNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.